Medtronic, Biosense tackle arrhythmias
This article was originally published in Clinica
Executive Summary
Medtech giant Medtronic and Johnson & Johnson subsidiary Biosense Webster are to collaborate on exploring new technologies for better diagnosing and treating patients with cardiac arrhythmias. The companies said they intend to combine Biosense's know-how in cardiac imaging and navigation with Medtronic's expertise in cardiac monitoring and diagnostics to create a new care protocol for identifying patients most likely to have a successful ablation treatment. The firms will also integrate their respective technologies to develop new therapies for complex cardiac arrhythmias under a joint R&D programme.
You may also be interested in...
P&G's $8M Benzene Settlement Preliminarily Approved By Ohio Federal Court
The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.
Food For Thought On US FDA Reforms
An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.
FDA’s Win-Win: More Comprehensive IND Safety Reports With Minimal Effort Due To Harmonization
New proposed rule calls for replacing US FDA’s current annual reporting requirements for INDs with a safety update report that is consistent the format and content of the development safety update report (DSUR) supported by the International Council of Harmonisiation.